The insider cluster is dominated by non-cash grants and routine director sales that are immaterial relative to HALO's $9.1B market cap. No C-suite executive sold shares on the open market. The $624K in open-market sales is noise. Monitor the next 10-Q for any fundamental changes, but this cluster provides no actionable trading signal.
HALO drugs
HALO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 6 $80.78entry
- T+1 · 4mo ago +0.98%α +1.45% · $81.57
- T+5 · 4mo ago −5.78%α −5.50% · $76.11
- T+20 · 4mo ago +1.84%α +0.99% · $82.27
- T+60 · 7w ago +38.10%α +36.38% · $111.56
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two HALO directors sold a combined $624K in open-market sales over a 3-day window, with the bulk ($548K) from Director Krishnan Mahesh following a derivative exercise. The total sales represent ~0.007% of HALO's $9.1B market cap, a trivial amount. The cluster is dominated by non-cash grants/awards to the CFO and EVP, which carry no economic signal. The open-market sales are small relative to company size and are likely routine portfolio diversification.
Key Financial Metrics
Key Facts
- Two directors sold a combined $624K in open-market sales over a 3-day window (June 29, July 1, 2026).
- Total open-market sales represent ~0.007% of HALO's $9.1B market cap, a trivial amount.
- The cluster is dominated by non-cash grants/awards to the CFO and EVP (208,041 shares at $0), which carry no economic signal.
- Director Krishnan Mahesh's sale ($548K) followed a derivative exercise, a common pattern for tax diversification, not a bearish signal.
- Director Connaughton Bernadette sold a small position ($124K), likely routine portfolio management.
- No C-suite executives made open-market sales; the CFO's transactions were all non-cash grants and awards.
Financial Impact
Total open-market sales of $624K represent ~0.007% of HALO's $9.1B market cap, a trivial amount.
Risk Factors
- No material risk identified from this insider activity, the cluster is too small to be informative.
- Director sales could increase if the stock continues to appreciate, but current levels are trivial.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-HALO-1783059252185 |
Track record
15 reports on HALO
1 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +17.70% at T+20 after the Oct 15, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 9, 20268d ago PTAB Trial Bearish 6/10 Entry $102.98 Now $96.50 +6.29% settles Nov 17
- Nov 6, 202610d ago Press Release Bullish 6/10 Entry $103.63 to $100.27 Now $96.50 −6.88% ▼ −3.24% −5.84% vs SPY
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $103.63 to $100.27 Now $96.50 −6.88% ▼ −3.24% −5.84% vs SPY
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $124.54 to $131.18 Now $96.50 −22.51% ▲ +5.33% +4.62% vs SPY
- Oct 20, 202627d ago Institutional Cluster Bullish 4/10 Entry $124.83 to $128.50 Now $96.50 −22.69% ▲ +2.94% +3.38% vs SPY
- Oct 15, 20264w ago PTAB Trial Bearish 7/10 Entry $121.84 to $125.63 Now $96.50 +20.80% ▼ −3.11% −3.54% vs SPY
- Oct 15, 20264w ago PTAB Trial Bearish 7/10 Entry $121.84 to $125.63 Now $96.50 +20.80% ▼ −3.11% −3.54% vs SPY
- Sep 18, 20268w ago 8-K Mixed 6/10 Entry $112.45 to $113.90 Now $96.50 −14.18% ▲ +1.29% +0.02% vs SPY
- Sep 17, 20268w ago Insider Cluster Neutral 2/10 Entry $112.45 to $113.90 Now $96.50 −14.18% ▲ +1.29% +0.02% vs SPY
- Aug 19, 202612w ago Insider Cluster Neutral 2/10 Entry $106.12 to $106.92 Now $96.50 −9.07% ▲ +0.75% −0.36% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers